AbbVie Inc. discovers, develops ... Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for ...

AbbVie already sells another long-acting treatment called Duopa, which delivers carbidopa and levodopa in an intestinal gel form via a gastric tube and pump, but that requires a surgical procedure ...

AbbVie Inc. discovers, develops ... Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. The biotech company reported in November ...

Gene therapy firm Capsida Biotherapeutics is advancing the first of its AbbVie-partnered neurodegenerative disease therapies after the Big Pharma exercised a $40 million option for the program.

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer ...

AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with ...

AbbVie ABBV underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of recent ratings by ...

AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company's key schizophrenia drug, emraclidine, The Wall Street ...

In an SEC filing, AbbVie ABBV has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share (EPS) by 88 cents due to in-process research and development ...